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Dysregulated IL-23/IL-17 responses have been linked to psoriatic arthritis and other forms of
spondyloarthritides (SpA). RORγt, the key Thelper17 (Th17) cell transcriptional regulator, is
also expressed by subsets of innate-like T cells, including invariant natural killer T (iNKT) and
γδ-T cells, but their contribution to SpA is still unclear. Here we describe the presence of
particular RORγt+T-betloPLZF− iNKT and γδ-hi T cell subsets in healthy peripheral blood.
RORγt+ iNKT and γδ-hi T cells show IL-23 mediated Th17-like immune responses and were
clearly enriched within inﬂamed joints of SpA patients where they act as major IL-17
secretors. SpA derived iNKT and γδ-T cells showed unique and Th17-skewed phenotype and
gene expression proﬁles. Strikingly, RORγt inhibition blocked γδ17 and iNKT17 cell function
while selectively sparing IL-22+ subsets. Overall, our ﬁndings highlight a unique diversity of
human RORγt+ T cells and underscore the potential of RORγt antagonism to modulate
aberrant type 17 responses.
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Spondyloarthritides (SpA) refers to a cluster of inﬂammatoryrheumatic diseases including ankylosing spondylitis (AS)and psoriatic arthritis (PsA), affecting nearly 1–2% of the
Western population. Typical disease manifestations consist of
inﬂammation of sacroiliac joints, as well as of the spine. Per-
ipheral joints can also be affected (peripheral arthritis), as well as
insertion of tendons to bone (enthesitis)1. Importantly, the dis-
ease also causes inﬂammation and tissue damage beyond
the musculoskeletal system with the most typically affected
organs being the eye (anterior uveitis), skin (psoriasis), and gut
(inﬂammatory bowel disease—IBD). This association is further
substantiated by a signiﬁcant overlap in the underlying genetic
predisposition for these disorders2. While the role for TNFα as
therapeutic target in SpA has been documented widely, an
emerging role for the IL-23/IL-17 inﬂammatory axis in this dis-
ease has arisen as evidenced by the marked efﬁcacy of IL-17a
inhibition (AS and PsA), as well as IL-12 and/or IL-23 blockade
(PsA)3–5. Curiously, IL-17 inhibition failed to demonstrate efﬁ-
cacy in patients with rheumatoid arthritis (RA) and IBD6,7. IL-23
and IL-17 show divergent roles on epithelial barrier integrity in
experimental models of gut inﬂammation8,9, which could explain
the dichotomy of clinical efﬁcacy of anti-IL-17 vs. IL-12/IL-23
inhibition in IBD patients, even though both are efﬁcacious on
joint symptoms in SpA. IL-22, the other IL-23 signature cytokine,
also plays a key role in the maintenance of mucosal homeostasis
by promotion of antimicrobial immunity, inﬂammation, and
tissue repair at barrier surfaces10. However, it is not completely
understood how differential expression of IL-17 and IL-22 is
regulated and potentially disturbed at the cellular level in SpA3.
IL-23 is necessary for the terminal differentiation and inﬂam-
matory functions associated with T helper-17 cells (Th17),
characterized by the expression of the key transcription factor
retinoic acid receptor-related orphan receptor-yt (RORγt; which
is encoded by RORC)11. Therefore, blockade of RORγt activity
may constitute an alternative to antibody-mediated cytokine and/
or receptor neutralization in treating IL-17-related diseases with a
potentially broader mode of action12. In addition to conventional
Th17 cells, other immune cells showing an innate(-like) pheno-
type, such as innate lymphoid cells (ILC), subsets of γδ-T cells,
mucosal associated invariant T (MAIT) cells and invariant nat-
ural killer T cells (iNKT) also express RORγt and IL-23 signature
cytokines13. Sherlock et al. showed that a speciﬁc subset of CD4-
CD8-unconventional T cells in mice (which are most likely γδ-T
cells) was able to drive SpA-like pathology upon induced systemic
overexpression of IL-23, independent of Th17 cells14. This sug-
gested that innate-like T cells may inﬂuence diseases like SpA15,
because they display plasticity, and could therefore be skewed
from an immunoprotective role towards a predominant IL-17
producing phenotype due to uncontrolled IL-23 signaling events.
iNKT and γδ-T cells are subpopulations of innate-like T cells,
which can release a broad spectrum of cytokines, both upon T cell
receptor (TCR) activation and after TCR-independent stimula-
tion, in this way acting as a ‘bridge’ between innate and adaptive
immune responses. iNKT cells are characterized by the expres-
sion of a semi-invariant TCR (invariant Vα24-Jα18 in humans)
associated with a restricted set of Vβ chains (Vβ11) and
they respond towards glycolipids, including microbial α-
glycuronylceramides and self-antigens, presented by the non-
polymorphic MHC class I-like molecule CD1d16. iNKT cells can
be separated into three distinctive subsets, iNKT1 cells, iNKT2
cells, and iNKT17 cells, analogous to the helper T cell lineage
nomenclature17. γδ-T cells show no distinct MHC class restric-
tion and are reactive towards both peptide (e.g., MHC related Ag
such as MICA) and non-peptide (e.g., isoprenoid metabolites)
antigens, by which they act as sensors of cellular stress and
infection danger18. Moreover, they appear to be major IL-17
producers in the initial phase of many bacterial infections19,20.
How human innate-like T cells such as iNKT and γδ-T cells are
involved in inﬂammatory responses in arthritic disease, particu-
larly SpA, is unclear and whether these cells can be skewed by
pharmacological modulation is equally unknown.
Here we identify novel innate-like T cell subset—RORγt+T-
betloPLZF− iNKT and γδ-hi T cells—circulating in healthy per-
ipheral blood and clearly expanded in inﬂamed joints, posed to
rapidly respond to IL-23 by steering Th17-like immune respon-
ses. By using FlowSOM21, we show a previously unappreciated
heterogeneity of human iNKT and γδ T cells of which speciﬁc
subsets are abnormally represented in the peripheral blood of
SpA patients. RNASeq analyses revealed a markedly distinct gene
signature proﬁle consistent with bias towards distinct IL-17
pathway regulation in innate-like T cells from SpA vs. RA
patients. Finally, pharmacologic modulation using RORγt inhi-
bition blocked effector function of disease associated subsets
while preserving IL-22 subsets, underscoring the potential of
RORγt antagonism to modulate aberrant type 17 responses.
Results and discussion
Human blood RORγt+ iNKT and γδ cells lack expression of
PLZF. Murine RORγt + IL-17 producing iNKT (also denomi-
nated iNKT17) and γδ-T cells (γδ17) have been extensively stu-
died but the prevalence and phenotype of their human
counterparts is poorly understood. We could delineate rare sub-
sets of RORγt+T-betlo iNKT (6B11+) and γδ-T cells in the blood
of healthy individuals (Fig. 1a and Supplementary Fig. 1A).
RORγt+T-betlo cells represented on average 2.1% (0.09–6%) of
total iNKT cells, comparable to frequencies of RORγt+T-betlo
cells (1.9 ± 1.4%; mean ± SEM %) detected in CD161+ Tconv
cells, a population enriched in Th17 cells22. The prevalence of
RORγt+T-betlo in the γδ-T population was less frequent (0.5 ±
0.4%), but still relatively increased compared to kindred cells in
the CD161- Tconv population (Fig. 1b). Interestingly, based on
TCR/CD3 expression levels, we could distinguish two populations
of γδ-T cells, a large fraction of TCRγδ-int cells and a minor
subset of TCRγδ-hi cells, with the latter showing a signiﬁcant
enrichment of RORγt+T-betlo cells (Fig. 1a, b). Phenotypical
different subsets of murine γδ-T cells have also been dis-
criminated based on TCR expression levels and/or γδ gene
usage23–25. Moreover, CD3bright γδ-T cells showing the canonical
Vγ6/Vδ1+ TCR have been correlated with the γδ17 phenotype
and these cells are preferentially found in lung and skin tissues of
mice25. With regard to TCR gene usage/TCR-δ repertoire of
human γδ subsets shown here, it was clear that the majority of
TCRγδ-int cells belonged to the δ2 TCR subfamily (being
Vγ9Vδ2), whereas TCRγδ-hi cells are enriched in δ1 cells
although they also included a minor subset of δ3 cells (Fig. 1c and
Supplementary Fig. 1B). The capacity of iNKT and these γδ-T
cells to secrete IL-17 and to a lesser extent IL-22 cytokines
(directly ex-vivo after short term PMA/CaI stimulation), was
consistent to their RORγt expression proﬁle (Fig. 1d and Sup-
plementary Fig. 1C).
In contrast to total iNKT and TCRγδ-int T cells, RORγt+T-
betlo iNKT and TCRγδ-hi T cells showed very low levels of
promyelocytic leukemia zinc ﬁnger (PLZF) (Fig. 1e, f and
Supplementary Fig. 1D). These ﬁndings could also be conﬁrmed
when using αGalCer-hCD1d tetramers for detection of iNKT cells
(Supplementary Fig. 1e, f). In mouse models it has been shown
that PLZF plays an important role in the early development of
iNKT cells26,27 and PLZF expression has also been identiﬁed in
MAIT cells28, innate subsets of γδ T cells29 and fetal ILC30,
suggesting a determinant role for PLZF in the common innate
phenotype of these cells. In humans, also NK cells and small
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subsets of CD4 and CD8 T cells seem to express PLZF31,
highlighting substantial differences in the importance of PLZF
gene expression between mice and humans. The low PLZF
expression in human blood iNKT17 cells seems to contrast
observations that PLZF regulates the acquisition and maintenance
of a human Th17 phenotype32. However, recent studies showed
that iNKT cells have a unique transcriptional proﬁle distinct from
that of NK cells and MHC-restricted T cells33. Moreover, the
transcriptional nature of iNKT17 cells was similar to analogous
subsets of γδ-T cells and ILC cells, while not to Th17 cells34. A
possible explanation could be that human RORγt+ iNKT cells
develop as a distinct subset of PLZFneg cells in the thymus. At
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least in mice this scenario seems unlikely, as thymic iNKT17 cells
express intermediate levels of PLZF, in between those measured
in iNKT1 (PLZFlo) and iNKT2 (PLZFhi) cells17. Alternatively,
iNKT17 cells might lose PLZF expression upon peripheral
migration and/or activation and differentiation. In this regard,
PLZFlo iNKT cells have been identiﬁed in murine adipose tissue,
not linked to RORγt expression or IL-17 production but to an
anti-inﬂammatory IL-10 driven phenotype, indicating a speciﬁc
local role for these PLZFlo iNKT cells in adipose tissue
immunoregulation35. In mice, iNKT17 cells are very scarce in
peripheral circulation and the majority of iNKT17 cells seem to
be tissue resident cells that can be found in lung tissue and lymph
nodes36. iNKT subsets are uniquely distributed in peripheral
lymphoid and non-lymphoid organs with some inter-strain
variation36. They do not (or only modestly) recirculate, but
instead show very long-term residence at these locations35,37. Our
data suggest that human peripheral blood RORγt+T-betlo
iNKT cells might show an intermediate/transitional phenotype
of iNKT17 cells, prior to migration of these cells into various
tissues, where they will further differentiate under inﬂuence of the
local microenvironment and signaling cues.
Most work on human γδ-T cells has focused on Vγ9Vδ2
T cells, which form the major population of blood γδ-T cells. Of
note, this subset is not found in mice due to the absence of
orthologous TCR gene segments18. We found that γδ-T cells
contain two phenotypically distinct subsets based on TCR
expression levels, with TCRγδ-hi cells being predominantly
PLZF+, GATA-3+, and Tbetlo. Although the data on the role
of PLZF in γδ-T cells are more limited, they also point towards an
innate differentiation program in these cells, as noticed for
selective subsets of murine (Vγ1+Vδ6.3/Vδ6.4+) γδ-T
cells29,31,38. In contrast, previous work indicated that PLZF is
present in all human γδ-T cells31, but our data highlight this is
especially true for the TCRγδ-int cell population, while TCRγδ-hi
cells, containing augmented numbers of RORγt+ cells (Fig. 1b),
are clearly PLZFlo. This seems in concordance with Kreslavsky
et al. showing that thymic mouse γδ-T cells capable of producing
IL-17 are PLZF negative29. However the majority of human
PLZFlo γδ-T cells did not express RORγt, so the precise relation
between expression of these transcription factors in γδ-T cells
needs further investigation.
Altogether, these data identify RORγt+ iNKT and γδ-hi T cells
as a minor fraction of PLZFneg innate-like T cells in the
peripheral blood of healthy individuals.
iNKT and γδ-T cells are armed for a competent IL-23 response.
As IL-23 and IL-23 receptor expression is clearly associated with
Th17 pathogenicity13, we examined IL-23 responsiveness of
human iNKT and TCRγδ T cell subsets. Consistent with data
obtained from IL-23R reporter mice39, we noticed that surface IL-
23R expression was almost completely absent on human blood
derived iNKT and TCRγδ T cells (Supplementary Fig. 2A). In
naïve mice, IL-23R is prominently found on lamina propria
lymphocytes (LPL) γδ-T cells39, underscoring the importance for
IL-23 at barrier sites. Using PrimeFlow technology, we measured
low but signiﬁcant amounts of RORCmRNA transcripts in iNKT,
TCRγδ-int, and CD161+ conventional T cells, in contrast to high
levels in TCRγδ-hi T cells (Fig. 2a and Supplementary Fig. 2B).
Interestingly, signiﬁcant IL-23 receptor (IL-23R) mRNA tran-
scripts could be found in iNKT cells, a subset of CD161+ T cells
and the majority of TCRγδ T cells. In addition to differences in
RORC mRNA, Il-23R mRNA was also expressed at higher levels
in TCRγδ-hi as compared to TCRγδ-int cells further under-
scoring the phenotypical variance between these γδ-T cell subsets.
Next, we tested blood TCRγδ and iNKT cell function in
response to IL-23 stimulation in vitro. As expected from the
absence of signiﬁcant surface IL-23R expression, short term
stimulation of sorted iNKT or TCRγδ T cells with IL-23 alone did
not lead to IL-17 release by any cell type (data not shown).
However, upon culturing iNKT or TCRγδ T cells with a TCR
stimulus (aGalCer or αCD3/CD28Ab, respectively), we found a
strong enrichment of IL-17 producing cells in those cultures
where we added IL-23 as compared to IL-2 alone (Fig. 2b), in
agreement with published data20,40. TCRγδ-hi cells showed an
augmented capacity to produce IL-17 and also IL-22 as compared
to TCRγδ-int cells upon IL-23 priming (Fig. 2b, c). TCRγδ-hi
cells producing IFNγ and TNFα were also induced by IL-23,
matching the frequencies found in TCRγδ-int cells. Parallel to
induction of IL-17, IL-23 skewed iNKT cells contained sig-
niﬁcantly increased numbers of IL-21+ cells, whereas the
frequency of IL-22, TNFα and IFNγ producing cells was
comparable between the IL-2 and IL-23 conditions (Fig. 2d).
The phenotypical proﬁle of IL-23 induced IL-17+ iNKT cells was
further evaluated by means of ﬂow cytometry and qPCR analyses
on sorted IL-17+ cells as obtained by a cytokine capture assay
(Fig. 2e, f). These data conﬁrmed that IL-23 induced iNKT17 cells
showed higher levels of RORC and lower levels of T-bet
expression and CD161 as compared to IL-17neg counterparts
(Fig. 2e and Supplementary Fig. 2C), mimicking the ex-vivo
phenotype (Fig. 1d). Moreover, iNKT17 cells also expressed
higher levels of CCR6 a chemokine receptor associated with Th17
cells, and contained high levels of IL17A, IL17F, and also IL22
mRNA (Fig. 2f).
Overall, these data indicate that human circulating iNKT cells
and especially γδ-hi T cells show signiﬁcant levels of IL23RmRNA
transcripts which enables them to rapidly induce Th17-like
immune responses.
iNKT and γδ-T cells in SpA joints show a IL-17 signature.
Because recent data point to the importance of IL-23/IL-17 driven
inﬂammation in mediating disease features in SpA, we examined
RORγt+ innate-like T cells in blood and synovial ﬂuid (SF) from
new onset SpA patients. We ﬁrst analyzed overall frequencies of
iNKT and TCRγδ T cell subsets in paired peripheral blood and SF
samples from patients with active joint swelling. The frequency of
blood circulating iNKT cells in SpA was signiﬁcantly reduced vs.
Fig. 1 Human blood circulating RORγt+ iNKT and γδ-T cells lack expression of PLZF. a Flowcytometric analyses showing distinct subsets of blood
circulating RORγt+T-betlo iNKT and total γδ-T cells (ﬂow plots show representative data from a healthy individual). Gating strategy is shown in
Supplementary Fig. 1A. b Percentages of RORγt+T-betlo cells in iNKT (n= 16) and γδ-T cells (n= 15) and CD161+ and CD161- Tconv (n= 11) (left panel;
*p < 0.05, **p < 0.01 as determined by ANOVA) and in γδ-T cell subsets (right panel; paired t-test). c TCRVδ proﬁling of indicated γδ-T cells (n= 6).
Representative ﬂow plots are shown in Supplementary Fig. 1B (d) IL-17 and IL-22 production by indicated subsets as measured by intracellular cytokine
staining after 4 h incubation of PBMC with PMA/CaI/BFA (stim) or BFA alone (no stim). Results from one experiment are shown (representative for
n= 6). Summary data are presented in Supplementary Fig. 1C. e Stacked histograms showing expression levels of PLZF, T-bet, GATA-3, and CD161
measured in iNKT and γδ-T cells (one representative example). f MFI values for indicated markers (as indicated in d). Each dot represents data from one
healthy individual (PLZF and GATA-3 n= 7; CD161 n= 9, T-bet n= 16). Overview of statistics (ANOVA) is provided in the Supplementary Table 3. Data
throughout this ﬁgure are presented as mean ± SEM
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Fig. 2 iNKT and γδ-T cells are armed for a competent IL-23 response. a RORC and IL23R mRNA transcripts expressed in iNKT, TCRγδ-hi/int, and CD161+
conventional T cells as measured by PrimeFlow technology (n= 3). Gray histograms represent FMO. Quantitative data are presented in Supplementary
Fig. 2B. b PBMC (left) or sorted γδ-T cells were cultured with αGalCer (PBMC, n= 18) or aCD3/aCD28 Abs (γδ-T cells, n= 6), in the presence of IL-2 or
IL-2 supplemented with IL-23, IL1β, TGFβ1 to induce IL-17 cytokine response as measured from viable iNKT (6B11+ TCRvβ11+ CD3+ cells) or γδ-T cells
(TCRγδ+ CD3+). Flow data from one representative experiment is shown. c, d Quantitative overview of cytokine production measured in γδ-T cell (C; IL-2:
black symbols; IL-23: red symbols) and iNKT (D, IL-2 condition: black symbols; IL-23: red symbols) cultures as described in b (IL-23 vs. IL-2 condition, *p <
0.05, **p < 0.01 determined by paired t-tests). e FACS analyses were performed on gated IL17+ and IL17− iNKT cells depicted in experiments described in
b (n= 6–8). *p < 0.05, **p < 0.01 determined by paired t-tests (IL-17- cells: black bars; IL-17+: white bars). f qPCR assays on selected target genes, were
performed on IL17+ and IL-17− iNKT cells isolated by means of a IL-17 Capture Assay (qPCR, n= 3, Mann-Whitney test). (IL-17- cells: black bars; IL-17+:
white bars). Data throughout this ﬁgure are presented as mean ± SEM
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age matched healthy controls (Fig. 3a, b; HC 0.130 ± 0.025% vs.
SpA 0.051 ± 0.008%; p < 0.01, ANOVA). By contrast, iNKT cell
numbers were increased in the SF samples of these patients
(0.168 ± 0.047%; p < 0.01 as compared to SpA blood). Frequencies
of γδ-T cells were not signiﬁcantly reduced in circulation of SpA
patients compared to healthy controls (Fig. 3c; HC 4.31 ± 0.41%
vs. SpA 3.34 ± 0.27%; p > 0.05, ANOVA). But curiously, in SF of
SpA patients the prevalence of especially the TCRγδ-hi subset was
remarkable augmented compared to peripheral blood (Fig. 3c;
SpA blood 25.8 ± 3.6% vs. SF 54.3 ± 4.7% of γδ cells; p < 0.01,
ANOVA). These alterations in iNKT and γδ-T cells were also
reﬂected in patient derived synovial tissue samples (inﬂamed
knee) (Supplementary Fig. 3). Moreover, there was also a sig-
niﬁcant increase in the number of IL-23R+ iNKT and γδ-T cells
in the joint compartment of SpA patients (Fig. 3d; iNKT: blood
4.3 ± 1.2% vs. SF 9.0 ± 2.2%; Fig. 5c γδ-T: blood 4.6 ± 1.7% vs. SF
17.9 ± 13.9% of γδ-T cells; both p < 0.01, ANOVA).
A hallmark of innate-like T cells such as iNKT and γδ-T cells is
their functional plasticity which is reminiscent, and may even
exceed, that of conventional CD4 T cells3. We therefore analyzed
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the transcription factors controlling effector functions in these
subsets in the blood and joints of SpA patients. RORγt+ cells in
iNKT and to lesser extent TCRγδ-hi, were signiﬁcantly enriched
in SF vs. blood and accompanied with a decrease in T-bet levels.
T-bet levels were also signiﬁcantly reduced in circulating
iNKT cells and γδ-T cells of SpA patients compared to controls
(Fig. 3e). In contrast, no signiﬁcant differences were found in
PLZF expression (Fig. 3e). The ﬂow cytometry dataset generated
from the patient and control samples was further evaluated by
FlowSOM, a novel and highly efﬁcient tool for unsupervised
clustering of cell types21. Traditional, linear analyses of multi-
parameter ﬂow cytometry data can suffer from limitations and
the recent progress in computational methods has led to novel
insights into immune cell diversity41. Human peripheral blood
iNKT and γδ-T cell subsets were visually represented in a
minimal spanning tree, where each node (circle) corresponds to a
group of phenotypically related cells, and neighboring circles
represent more similar cell types (Fig. 3f). FlowSOM metacluster
analyses showed a marked heterogeneity of blood circulating
iNKT and γδ-T cell subsets (based on their transcriptional factor
proﬁle). Moreover, we observed a skewing of particular innate-
like T cell subsets in the blood of SpA patients, which was most
pronounced for iNKT cells (Fig. 3f and Supplementary Fig. 4).
SpA patient blood circulating conventional T cells showed a
comparable FlowSOM proﬁle with corresponding cells from
control individuals, although some minor signiﬁcant differences
were observed for the CD161+ population (Supplementary Fig. 4
and 5). When we evaluated their cytokine production (directly
ex-vivo after short term PMA/CaI stimulation), we observed
increased numbers of IL-17+ cells in blood derived iNKT and
TCRγδ but not Tconv cells from SpA patient vs. healthy controls
(Fig. 3g; iNKT 2.81 ± 0.64% vs. 8.20 ± 2.27% IL-17+ ; γδ: 1.16 ±
0.21% vs. 2.97 ± 0.80% IL-17+ for HC vs. SpA, respectively; both
p < 0.05, ANOVA). Moreover, innate-like T cells represent about
half of all IL-17 producing blood circulating T cells, and this
fraction is even higher in SpA (Fig. 3h and Supplementary
Fig. 6A).
iNKT and γδ-T cells were found to be even further skewed
towards RORγt and IL-17 expressing subsets in SF samples from
SpA patients (Fig. 4a, b) as determined by FLOWSOM (Fig. 4a)
and intracellular cytokine stainings (Fig. 4b). Moreover, elevated
RORγt expression levels were also measured in synovial tissue
residing iNKT and γδ-T cells (Supplementary Fig. 3). To assess
the contribution of these innate-like T cells in IL-17 inﬂammation
in the joints, we selectively depleted iNKT and γδ-T cells from
SpA SF mononuclear cells (SFMC) and assessed the impact on
cytokine production following TCR ligation. For this, we
measured IL-17 and IL-22 (next to TNFα and IFNγ) secretion
in cultures of SFMC in the presence or absence of iNKT and
TCRγδ cells (SFMC and ΔSFMC, respectively). Both SFMC and
ΔSFMC fractions were processed under identical conditions and
stimulated with or without IL-23 and in the absence or presence
of TCR stimulation (Fig. 4c). These experiments highlighted that
the absence of iNKT/TCRγδ cells led to a marked decrease in IL-
17, IL-22, and IFNγ production upon TCR ligation, a ﬁnding also
observed under different stimulation conditions (Supplementary
Fig. 6B). TNFα levels did not signiﬁcantly change in ΔSFMC vs.
SFMC cells (Fig. 4c). Interestingly, IL-23 alone also induced some
IL-17 in SFMC but not in ΔSFMC cells (Fig. 4c) consistent with
the observed IL-23R abundance on these cells in the joint
compartment. These functional data provide clear evidence that
innate-like T cells such as iNKT and γδ-T cells, although
numerically not the most abundant immune cell subset, act as
major T cell sources of IL-17, IL-22, and IFNγ in SpA joints.
Taken together, there is a previously unrecognized diversity of
human innate-like T cells of which some RORγt+ subsets show a
particular skewing in SpA patient blood and joint ﬂuid. Thus,
RORγt+ iNKT and γδ-T cells accumulate in joints of patients
with SpA, and potentially together with other innate-like immune
cells such as MAIT42 and ILC43,44 act as major contributors to IL-
17 mediated pathology in SpA joints.
iNKT and γδ-T cells show different gene expression proﬁles in
SpA and RA. RA is a chronic autoimmune joint disease which
has also been linked to Th17 mediated pathology45. Unexpect-
edly, inhibition of IL-17A with secukinumab, as showed in
a phase 3 clinical trial, failed to demonstrate major clinical ben-
eﬁts7, which contrast with its broad efﬁcacy in SpA4. We there-
fore evaluated whether the altered iNKT17 and γδ17 T cell proﬁle
we observed was a speciﬁc ﬁnding for SpA. We ﬁrst evaluated
iNKT and γδ-T cell numbers in blood and SF samples of treat-
ment naïve RA patients in addition to patients with crystal
induced arthritis (CrA, including gout/chondrocalcinosis), pro-
totypic forms of acute –inﬂammasome/IL-1- driven arthritis46
(Fig. 5a). An enrichment of iNKT cells in peripheral joints was
also observed in RA patients, but not in CrA patients Fig. 5a).
There were no signiﬁcant differences in total TCRγδ+ cell
numbers in blood vs. SF samples from RA nor CrA patient and
only SpA patients showed a signiﬁcant increase in IL-23R+ γδ-hi
cells in the joints (Fig. 5b, c). Notable, there was a subset of IL-
23R+ γδ-T cells clearly present in the SF of CrA patients (Fig. 5c).
This seems unrelated to observations in SpA, as these CrA patient
γδ-T cells were not enriched in TCRγδ-hi cells. Whether these
Fig. 3 iNKT and γδ-T cells in SpA joints show a profound IL-17 signature. a Flowcytometric analyses of iNKT and γδ-T cells in paired PBMC and SFMC
derived from a representative SpA patient. bMean percentage (±SEM) of iNKT cells (relative to total CD3+ T cells) measured in PBMC (SpA, n= 33; HC,
n= 27) and SFMC (SpA, n= 18) samples (**p < 0.01 as determined by ANOVA). c Frequency of γδ-T cells and TCRγδ-hi cells (relative to total CD3+
T cells and γδ-T cells, respectively) in PBMC and SFMC samples (ANOVA). d Mean percentage IL-23R+ cells (relative to iNKT cells) measured in PBMC
and SFMC samples from B (ANOVA). e Transcriptional factor proﬁle of iNKT cells and γδ-T cells measured in PBMC and SFMC from SpA patients (PB n=
8-12, SF n= 4-8) and HC (n= 8-16). (*p < 0.05 as determined by ANOVA) (HC-PB: white bars, SpA-PB: black bars, SpA-SF: Red bars). f FlowSOM
visualization of indicated immune cell population present in the peripheral blood of HC (n= 8) and SpA patients (n= 8), stained for markers indicated in
the pie chart. Each circle represents a speciﬁc marker combination, corresponding to a speciﬁc cell type. The mean marker values are visualized for each
node, using star charts. The height of each part indicates the expression intensity: if the part reaches the border of the circle, the cells have a high
expression for that marker. The nodes are connected to the ones they are the most similar to. An automatic meta-clustering of the FlowSOM nodes is
visualized by the background color of groups of nodes. A parallel tree gives an overview of signiﬁcantly over-(red) or under-(blue) represented cell types in
SpA patients vs. controls. g IL-17 and IL-22 production by peripheral blood iNKT and γδ-T cells from SpA patients (n= 10; black bars) and controls (n= 10,
white bars) as measured by intracellular cytokine staining after 4 h incubation of cells with PMA/CaI in the presence of BFA (*p < 0.05, t-tests HC vs.
SpA). h Relative representation of indicated peripheral blood T cell subsets among IL-17 producing T cells as measured in PMA/CaI stimulated PBMC from
HC and SpA patients (see Supplementary Fig. 6A for individual data points and statistics). Data throughout this ﬁgure are presented as mean ± SEM unless
stated otherwise
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cells are potentially driven by uric acid crystal induced IL-1 sig-
naling events needs additional study.
We sorted peripheral blood iNKT and TCRγδ T cells next to
CD161− Tconv cells from 7 SpA and 5 RA patients prior to gene
expression proﬁle analyses. Principal component analysis (PCA)
of normalized transcriptomics data showed separate clustering of
iNKT cells of RA patients and SpA patients and to a lesser extent
also for γδ-T cells and Tconv cells indicating clear differences in
gene expression proﬁles between SpA and RA patients (Fig. 5d).
Next, differentially expressed genes in SpA vs. RA derived cells
were evaluated and volcano plots were generated showing genes
(red dots) at least 2 fold upregulated in either SpA or RA
(adjusted p < 0.05) (Fig. 5e). Pairwise comparison of iNKT, γδ-T
cells and Tconv of SpA and RA patients indicated 1594, 168, and
1206, respectively, differentially expressed genes. When compar-
ing cells from SpA and RA patients, we detected no signiﬁcant
differences in expression of the Th cell signature transcription
factors, RORC (Th17), TXB21 (Th1) or GATA3 (Th2), for any of
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the investigated T cell subsets. Interestingly, for iNKT cells, there
was clear upregulation of iNKT17 associated genes (AHR, SGK1,
RUNX3, and ICOS) in SpA and upregulation of iNKT1 associated
genes (CD244, CSF1R, EOMES, CCR5) in RA. The overexpression
AHR and SGK1 mRNA in SpA vs. RA immune cells are of
interest as they are known to be triggered by environmental
signals. Indeed, AHR (Aryl Hydrocarbon Receptor) encodes for a
ligand-activated nuclear transcription factor which has been
shown to be expressed by iNKT17 cells, although rather promotes
IL-22 secretion while suppressing IL-1740. AHR activation is
0.001
0.01
0.1
1
*
**
**
**
%
iN
KT
 c
el
ls
%
TC
Rγ
δ 
ce
lls
0.1
1
10
100
Th1
TBX21
EOMES
STAT4
IL12RB2
CXCR3
CCR5
CX3CR1
GATA3
IRF4
STAT6
RORC
AHR
RUNX3
STAT3
IL23R
CCR6
SGK1
1.5
1
0.5
–0.5
–1.5
–1
0
Th2
Th17
PB
SF
0
20
40
60
80
**
PB
SF
0
20
40
60
80
**
**
*
*
% γδ hi
%IL-23R
iNKT
Tconv
RA
Log2 fold change
SpA
RA
PC1 (49.71%)
PC2 (12.61%)
PC1 (35.39%)
PC2 (21.06%)
PC1 (54.22%)
PC2 (16.99%)
iNKT
Tconv
2.5 5.0–2.5–5.0 0
105.0–5–10 0 15–15
10
0
–10
–30
–20
40
20
–20
0
30
20
10
–10
0
–20
–
lo
g1
0 
p
-
va
lu
e
0
1
2
3
4
–
lo
g1
0 
p
-
va
lu
e
0
0.5
1
1.5
2
–
lo
g1
0 
p
-
va
lu
e
0
2
4
6
γδ T
γδ T
2.50 5.0–2.5–5.0
SpA
HC SpA RA CrA
HC SpA RA CrA
%
 o
f T
CR
-γδ
%
 o
f T
CR
-γδ
SpAHC RA CrA
SpAHC RA CrA
CSF1R
CCR5
CD244
EOMES
RORC
GATA3 TBX21
ZBTB16
SOX4
KIR2DL3
GATA3
TNFSF13B
CXCR1
SYK
ZBTB16
TBX21
RORC
RUNX3
KIR2DL3
SIK1
GATA3
SGK1
CCL5
ZBTB16
TBX21
RORC
CXCR6
TNFRSF1A
IL6R
TNFAIP8L2
KIR3DL1
SGK1
AHR
RUNX3
ICOS
a b
c
d e f
γδiNKT
Sp
A
R
A
Sp
A
R
A
Sp
A
R
A
Tconv
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07911-6 ARTICLE
NATURE COMMUNICATIONS |            (2019) 10:9 | https://doi.org/10.1038/s41467-018-07911-6 | www.nature.com/naturecommunications 9
induced by naturally occurring compounds such as tryptophan
metabolites (derived from microorganisms), next to synthetic
polycyclic aromatic hydrocarbons and dioxin-like compounds47.
SGK1 (Serum/Glucocorticoid Regulated Kinase 1) gene expression
in iNKT cells has not been described yet, but may be critically
important as this kinase is involved in salt induced signaling
processes and it is able to promote Th17 function while
suppressing Treg function48,49. In addition, γδ-T cells of SpA
patients differed substantially from RA by a remarkable
upregulation of SOX4, a high-mobility group (HMG) box
transcription factor, key in γδ17 cell-speciﬁc transcription
program50, whereas we noted that IL18RA (CXCR1) and BAFF
were signiﬁcantly higher expressed in RA. BAFF, is a key cytokine
for B cell activation and maturation, mainly expressed by myeloid
cells and stromal cells, but it was recently also shown to be
expressed by human TCRγδ cells upon TGF-β/IL-15 stimula-
tion51. Finally, Heatmap visualization of typical Th cell genes
demonstrated that innate-like T cell subsets, especially iNKT, to
be more skewed towards a Th17 cell associated proﬁle in SpA as
compared to RA (Fig. 5f)
In addition to these marked differences in innate-like T cells,
also conventional T cells displayed some marked differences
between SpA and RA. This included expression of several Killer
cell immunoglobulin-like receptors (KIRs), transmembrane
glycoproteins expressed by natural killer cells and subsets of
T cells, which were upregulated in SpA patients. For example,
KIR3DL1 was reported to act as a receptor for HLA-B27
homodimers52 representing a mechanism by which HLA-B27
may be linked to aberrant NK and T cell responses in SpA53. By
contrast, RA conventional T cells showed increased IL6R mRNA
levels, as well as differences in expression of TNF signaling genes
such as TNFRSF1A (encoding the TNFR1) and TNFAIP8L2
(TIPE2), both previously linked to RA disease pathogenesis54.
Collectively our data provides evidence for a “type 17” skewed
gene expression proﬁle in SpA innate-like Tcells and this appears
to be a discriminative feature compared to other forms of arthritis
such as RA.
RORγt inhibition selectively blocks innate-like T cells. Because
Il-17 and/or Il-23 inhibition has demonstrated marked ther-
apeutic efﬁcacy in psoriasis, PsA and AS, a potential alternative
strategy therefore includes RORγt inhibition by cost-effective
small molecules. However, there are still several unanswered
questions as to the impact of RORγt blockade on IL-17 and/or IL-
23 mediated immunity as a consequence thereof and whether this
impacts all Th17 related cytokines similarly. Several RORγt
antagonists or inverse agonists (such as digoxin, SR1001 TMP778,
GSK805, and MRL-871, JNJ-54271074) have been identiﬁed and
tested in different disease models55–59. Here, we describe a new
and very potent RORγt agonist/inhibitor, BIX119. This com-
pound strongly bound to and selectively inhibited the human
RORγ ligand-binding domain. In functional cell assays, BIX119
clearly abolished the induction of Th17 cells from human CD4+
T cells and dose dependently suppressed IL-17 by reactivated
Th17 cells (Fig. 6a), verifying that it is a selective and potent
RORγt inhibitor. It abolished IL-17 and IL-22 production in both
CD4+ T cell and bulk PBMC cultures upon TCR stimulation
(Fig. 6b and Supplementary Fig. 7A). Surprisingly, when BIX119
was added in cultures of IL-23 skewed human iNKT and γδ-T
cells, we observed a signiﬁcant inhibition of IL-17 but not of IL-
22 secretion (Fig. 6c-e). Likewise, restimulation of IL-23 skewed
cells in the presence of BIX119 led to a selective blocking of IL-17
but not IL-22 secretion (Supplementary Fig. 7B).
Human iNKT cells display a profound heterogeneity with
regard to IL-17 and IL-22 production. We found single IL-17 and
single IL-22 producing cells, next to a signiﬁcant subset of double
(IL-17+IL-22+) cytokine producers (Supplementary Fig. 7C).
Interestingly, IL-17+IL-22− and IL-17+IL-22+cells expressed
equally high levels of RORγt whereas single IL-17 producers
clearly differed from other subsets by reduced T-bet levels
(Fig. 6f). The IL-22 single producers had an intermediate level of
RORγt expression (Fig. 6f). We also subjected this dataset to
FlowSOM analyses and found that BIX119 signiﬁcantly inhibited
induction of several IL-17 producing iNKT subsets (Fig. 6g and
Supplementary Fig. 8). RORγt inhibition shifted the balance from
IL-17 producing cells towards a iNKT1 phenotype, while also
increasing the prevalence of particular subsets of IL-22 producing
cells (Fig. 6g and Supplementary Fig. 8). Thus, RORγt inhibition
does not only seems to repress iNKT17 immunity, it bypasses
subsets of IL23 induced IL-22 producing cells.
Our data show that innate-like T cells such as iNKT and γδ-T
cells are expanded and functionally skewed towards Il-17
secretion in SpA, diseases in which barrier integrity loss in skin
or gut seems to sensitize the disease. Importantly, these subsets
characterized by a unique transcription factor proﬁle dominated
by RORγt are clearly expanded in the circulation and even more
in inﬂamed joints, highlighting the importance of these subsets in
SpA. Quite unexpectedly we found that innate-like T cells differ
substantially from conventional Th17 cells in cytokine regulation
by RORγt57,60,61, Earlier in-vivo studies indicated that transient
blocking of RORγt allows for selective targeting of Th17 cells
without inﬂuencing protective ILC3 responses62. In addition,
pharmacological inhibition of RORγt can modulate TCRα gene
rearrangement taken place in developing thymic T lymphocytes
and by this moderately limited the T cell repertoire diversity in
peripheral circulation63. It was not reported whether this
inﬂuenced iNKT development in treated mice, a ﬁnding shown
in patients with loss-of-function mutations in the RORC gene64.
By unsupervised computational analysis of ﬂow cytometry data
we uncovered a previously unappreciated complexity of both
human γδ-T and iNKT cells as we show that RORγt inhibition
not only efﬁciently blocks Th17 function, but also ablated human
IL-17 producing γδ-T cells and iNKT cells while selectively
sparing IL-22+ subsets. These results conﬁrm that IL-22 can be
secreted by innate-like T cells independently from RORC driven
Fig. 5 iNKT and γδ-T cells show different gene expression proﬁles in SpA and RA patients. a Frequencies of iNKT and γδ-T cells in indicated groups of
rheumatic patients (each dot represents data from a single patient). Statistical analyses (*p < 0.05, **p < 0.01) referred to comparisons of blood samples
(patients vs. controls) and comparisons of SF as compared to paired blood samples of patients as done by ANOVA and paired t-tests, respectively (same
for b and c). (PB: black symbols; SF: red symbols) b Relative percentage of TCRγδ-hi cells and c IL-23R (lower panel) in γδ-T cells of samples taken from
patients and controls. (PB: white bars; SF: red bars) d Principal component analysis (PCA) of transcriptomes (RNAseq data) of iNKT, γδ-T and Tconv cells
sorted from SpA (n= 7, red) and RA patients (n= 5, blue). Each sphere symbol represents an individual patient. e Differentially expressed genes are
represented in Volcano plots after pairwise comparisons between indicated subsets of SpA and RA patients. Each symbol represents a single gene and
genes of interest are highlighted (see also main text). Color coding refers to differentially expressed genes with adjusted p-value less than 0.05 and the
log2FC less than −1 (higher expressed in RA derived cells) or greater than 1 (higher expressed in SpA). f Heatmap showing relative expression Th1, Th2,
and Th17 related genes in indicated cell subsets from SpA and RA patients. Data throughout this ﬁgure are presented as mean ± SEM
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IL-17 production, potentially by AHR signaling. Given the
established gut-joint axis in SpA, this can be of clinical
importance as IL-22 plays a protective role at gut barrier
surfaces10, sites known to be enriched in innate-like (T) cells.
AHR signaling in gut mucosal ILC cells has been shown to be
responsible for an IL-22 dependent modulation of immune
responses against mucosal microbiota and protecting mice from
exacerbated colitis65,66. Given that IL-17 also mediated protective
barrier function in the gut, these data point to a delicate and
complex network of pro-inﬂammatory and anti-inﬂammatory
signals involved in host protection. A shift in these immune
processes in susceptible individuals may tip the balance toward
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disease initiating events in SpA67. Whether AHR mediated
responses are altered is appealing given the increased AHR gene
expression we observed in blood circulating iNKT cells in SpA
patients. This however warrants additional investigation of
innate-like T cells in gut samples from SpA patients67.
A decrease of blood iNKT cells and a relative enrichment of
these cells in the joint compartment of SpA patients may also
reﬂect shifts in iNKT cell subsets due to migration of pathogenic
subsets toward sites of inﬂammation. In vivo evidence for such a
scenario was very recently provided by the Kronenberg team
showing an accumulation of iNKT cells in ankle joints upon
progression of mannan induced arthritis in SKG mice68.
Interestingly, this coincided with a progressive increase of
iNKT17 cells in the inﬂamed joint tissue at the expense of
protective IFNγ secreting iNKT1 cells. Alternatively, iNKT1 cells
in SpA could be more susceptible towards transition to an
iNKT17 cell phenotype under inﬂammatory conditions40. T-bet
acts as a repressor of the IL-23/IL-17 immune pathway69. So the
low T-bet expression in innate-like T cells observed in SpA
patients could contribute itself to uncontrolled IL23 mediated
pathology.
Collectively these data point to a distinctive regulation of
innate-like T cells in SpA with a Th17-skewed phenotype and our
data are clearly supportive for the progress in putting forward
RORγt antagonism, targeting these cells, as a potential promising
new therapeutic approach.
Methods
Human samples. Blood samples were obtained from 27 healthy control subjects
and 33 patients with newly diagnosed SpA. Synovial ﬂuid (SF) was obtained from
patients with an active knee synovitis and an indication for aspiration. Rheumatoid
arthritis (RA, n= 17) and Crystal-induced arthropathies (CrA, n= 11) patients,
were included as a chronic and acute inﬂammatory arthritis comparison group,
respectively. For details on the demographic and clinical characteristics of the
patients, see Supplementary Table 1. Diagnosis and classiﬁcation of patients was
made by staff rheumatologists following the EULAR/ American College of Rheu-
matology (ACR) 2010 or ASessment in Ankylosing Spondylitis (ASAS) 2010 cri-
teria. Patients were treatment naïve or under treatment with a NSAID and/or
DMARD (Methotrexate, Sulfasalazin), but naïve for treatment with biologicals at
the time op sampling (see Supplementary Table 1). Ultrasound guided synovial
biopsy sampling of knee joints was done by an experienced rheumatologist in our
early arthritis clinic. At least six biopsies were taken to ensure enough cellular
material (>500,000 cells) could be extracted for ﬂow analyses. This study was
approved by the local ethics committee of Ghent University Hospital and all
patients and healthy controls gave written informed consent.
Cell isolation. PBMC and SFMC were directly isolated from PB and SF samples as
described before70. Synovial tissue samples were digested with a mixture of Col-
lagenase IV and VIII (Sigma, both 1 mg/ml) for 30 min at 30 °C under continuous
stirring conditions. Digested samples were ﬁltrated (40 µm), washed and prepared
for ﬂow cytometric analyses as indicated below. Blood γδ-T cells (TCRγδ+) and
iNKT cells (TCRVα24+ TCRVβ11+) were sorted on a FACSAria III (BD). The
latter cells were expanded by 6B11 stimulation as described in ref. 71. IL-17+
iNKT cells were isolated by means of an adapted IL-17 Capture Assay (Cell
Enrichment and Detection Kit, Miltenyi Biotec). Brieﬂy, two weeks after αGalCer
(100 ng/ml) and IL-23 stimulation, PBMC were restimulated with Cytostim
(Miltenyi Biotec; crosslinking TCR and MHC) for 4 h at 37 °C. Subsequently, cells
were labeled with IL-17 Catch Reagent, by which cell secreted IL-17 is bound at the
cell membrane. Finally, cells are labeled with an APC labeled IL-17 detection
antibody, next to 7-aminoactinomycin D (7-AAD; for life/dead discrimination)
and antibodies directed against TCRVα24 and TCRVβ11, prior to FACSorting of
IL-17+ TCRvα24TCRvβ11+ 7-AADneg cells. A negative (no Cytostim) and positive
(PMA/CaI/BFA) control condition was used in each experiment.
Cell cultures. For iNKT assays, PBMC were cultured in 24-well plates (1.5 × 106
cells/well) for 14days in the presence of αGalCer (100 ng/mL, in house made) and
IL-23 (20 ng/mL), IL-1β (10 ng/mL), TGFβ1 (5 ng/mL; all eBioscience), and IL-2
(5 U/mL, Roche) or IL-2 alone. Similar experiments were performed with sorted
iNKT and γδ-T cells in U bottom 96 well plates (50,000 cells/well) where we added
50,000 irradiated (40 Gy) T cell depleted PBMC cells (using CD2 dynabeads,
ThermoFisher) as feeder/antigen presenting cells. Cytokine titers in supernatants
were then determined by ELISA (ebioscience) or multiplex protein assays (MSD).
SFMC depletion assay. SFMC from SpA patients (n= 3) were split in two equal
fractions (I and II). Both fractions underwent a similar sorting procedure to
exclude a potential bias on functionality. Fraction I was labeled only with 7-AAD to
exclude dead cells. Cells from fraction II were labeled with anti- human TCRVβ11,
6B11 and TCRγδ and 7-AAD. Fraction I and II were acquired on a FACSAria III
sorter (BD) at the same ﬂow rate and gated for live lymphocytes (7-AADneg FSClo/
SSClo). Fraction II was depleted of iNKT (TCRVβ11+ 6B11+) and γδ-T cells
(TCRγδ+) cells by negative gating (see Fig. 4c). Equal cell numbers (min. 300,000)
from sorted SFMC and SFMC cells depleted of iNKT and TCRγδ cells (ΔSFMC)
were cultured in 96 ﬂat bottom plates. For TCR stimulation, wells were (prior to
cell adition) plate coated with aCD3Ab and aCD28Ab (both at 5 µg/ml in PBS, BD)
overnight at 4 °C. Wells indicated for non-TCR stimulated conditions were incu-
bated with PBS only. Wells were washed extensively before cells were added. IL-23
(20 ng/ml) together with IL-1β (10 ng/ml) and TGFβ1 (5 ng/ml) resuspended in
culture medium was added to indicated wells (“IL-23” condition). Non cytokine
stimulated wells were incubated with medium only (“no IL-23”). Supernatants of
cultures were collected at 72 h of culture and in levels of IL-17, IL-22, TNFα, and
IFNγ were determined by ELISA (eBiosciences).
Flow cytometry. Eight–ten color ﬂow cytometry was applied to PBMC and SFMC
samples and isolated (cultured) cells as described before70,71, using ﬂuorochrome
conjugated antibodies as summarized in Supplementary Table 2. iNKT cells
(CD3+ 6B11+ TCRVβ11+), γδ-T cells (CD3+ TCRγδ+) and CD161+ and
CD161− conventional Tconv (T cells excluded from innate-like T cells, CD3+
TCRγδ− TCRVα7.2-TCRVα24Jα18−) were gated as shown in Supplementary Fig.
1A. Human aGalCer loaded CD1d tetramer (in house produced) was used to verify
iNKT stainings as indicated in Supplementary Figure 1E-F). FcR Blocking Reagent
(Miltenyi Biotec) was used to exclude aspeciﬁc FcR binding of Abs. For ﬂowcy-
tometric analyses of cultured cells, Ab staining was preceded by incubation with
viable cell discriminating reagents (LIVE/DEAD® Fixable Violet Dead Cell Stain
Kit, ThermoFisher or Fixable Viability Stain 520, BD). A minimum of 500 iNKT
and 3000 γδ-T cells were acquired on a FACS Canto II or Aria III machine (BD) to
guarantee accurate calculations of the expression of differentiation markers/tran-
scription factors by these cells. Data analyses and graph presentations were done by
means of FlowJo software, v9.8 and 10.2 (Treestar). Prior to intracellular staining of
transcription factors, the cells were ﬁxed and permeabilized using the reagents and
following the instructions of the FoxP3 intracellular staining kit (eBioscience). For
cytokine stainings, cells were collected and restimulated for 4 h with PMA (25 ng/
mL), calcium-ionomycin (1 µg/mL; both from Sigma) and brefeldin A (10 ng/mL;
Fig. 6 RORC inhibition selectively blocks innate-like T cell function. a Upper panel: healthy donor CD4+ T cells cultured under Th17 conditions for 7 days.
Data is represented as % IL-17+ cells as determined by intracellular ﬂow cytometry (n= 4). (*p < 0.05, **p < 0.01 as determined by ANOVA). Lower panel:
Skewed CD4+ Th17 cells were re-stimulated under Th17 conditions for 48 h and IL-17 levels were measured in the supernatants. Dose response of the
RORγt antagonist (BIX119) for three donors is shown. b Human PBMC activated with aCD3Ab and IL-23 for 72 h. Dose response of the RORγt antagonist is
shown for IL-17A and IL-22 secretion detected in culture supernatants by ELISA (n= 3). c γδ-T cells were activated with anti-CD3/CD28 beads and IL-23
cocktail for four days to produce IL-17A and IL-22 in the presence of increasing concentrations of RORγt antagonist BIX119 (n= 5). *p < 0.05 as compared
to no compound (ANOVA) (d) PBMC were stimulated with αGalCer in the presence of IL-2 or IL-23 cocktail with addition of BIX119 (1 µM) or DMSO. After
14 days, cells were restimulated with PMA/CaI (with BFA) for intracellular cytokine detection. One example representative for three independent
experiments is shown. The negative control (neg ctr) consisted of IL-23 skewed cells cultured in BFA alone. e quantitative overview of frequency of IL-17,
IL-22 and TNFα+ iNKT cells from assays described in D (**p < 0.01 by paired t-tests). f IL-23 skewed iNKT cells were analyzed for RORγt and T-bet
expression by intranuclear ﬂow cytometry. Gating on cytokine producing iNKT cells was performed as illustrated in supplementary ﬁgure 7C (*p < 0.05,
**p < 0.01 ANOVA). g FlowSOM visualization (as explained in Fig. 3F) of IL-23 skewed human iNKT cells (n= 3), cultured in the presence or absence of
the BIX119 RORγt antagonist (compound). Pie chart shows markers used for automated clustering of iNKT cell types. Data throughout this ﬁgure are
presented as mean ± SEM
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BD). Subsequently, cells were processed using the Cytoﬁx/Cytoperm kit (BD) as
described before70.
RORC and Il23R mRNA expression on speciﬁc T cell subsets was measured by
means of a PrimeFlow RNA Assay (eBioscience), using VA1 and VA4 probes,
respectively, and following the manufacturer’s instructions. Proper positive and
negative controls (RPL13A and FMO) were included in each assay.
qPCR. Cells were lysed using RLT lysis buffer supplemented with βmercapto-
ethanol (Qiagen) and were kept at −80 °C until analysis. RNA extraction and
cDNA preparation were conducted using the RNeasy mini kit (Qiagen) and the
QuantiTect Reverse Transcription Kit (Qiagen), according to the manufacturer’s
instructions. qPCR reactions were performed in duplicate using a LightCycler
480 system (Roche). QuantiTect primer assays for IL17A, IL17F, IL22, RORC, and
IL23R genes were ordered from Qiagen. Reference (housekeeping) genes were
designed, validated and tested for stable expression (including Gapdh, β-actin and
HPRT) and data were analyzed using qbase+ (Biogazelle).
RNASeq. PBMC were isolated from freshly taken blood samples of treatment naïve
SpA patients (n= 7) and RA patients (n= 5) as described above. Cells were labeled
with anti-human TCRVβ11, 6B11, CD161, CD3, TCRγδ and 7-AAD to exclude
dead cells. iNKT (CD3+ TCRVb11+ 6B11+), γδ-T cells (CD3+ TCRγδ+) cells
and Tconv (CD3+ CD161-; negative for iNKT and γδ-T markers) were sorted on
a FACSAria III (BD) and immediately stored in RLT (Qiagen) +1% β-
Mercaptoethanol (Sigma) at −80 °C. RNA was isolated by means of the RNeasy
Micro kit following manufacturer’s instructions (Qiagen). RNA concentration and
purity were determined spectrophotometrically using the Nanodrop ND-1000
(Nanodrop Technologies) and RNA integrity was assessed using a Bioanalyser 2100
(Agilent). Per sample, an amount of 100 pg (iNKT) or 1 ng (γδ and Tconv) of total
RNA was used as input for the SMART-Seq v4 Ultra Low Input RNA protocol
(version 091817) from Takara Bio USA, Inc. Subsequently, 1 ng (iNKT) or 2 ng
(γδ-T and Tconv samples) of puriﬁed cDNA was sheared to 300 bp using the
Covaris M220. From the sheared material, sequencing libraries were prepared with
the NEBNext Ultra DNA Library Prep Kit for Illumina (version 6.0–2/18),
according to the manufacturer’s protocol including a size selection to 250 bp insert
size. Sequence-libraries of each sample were ﬁnally equimolarly pooled and
sequenced on 4 NextSeq500 v2 ﬂow-cell at 1 × 75 bp (76–8–8–0). The preproces-
sing of the RNA sequencing data was done by Trimmomatic. The adapters were cut
off, and reads were trimmed when the quality dropped below 20. Reads with a
length <35 were discarded. All samples passed quality control based on the results
of FastQC. Reads were mapped to the human reference genome (hg19) via Tophat2
and counted via HTSeqCount. Samples were subsequently analyzed using R/Bio-
conductor, and the R package limma was used to normalize the data and to do
differential expression analysis. The 3 cell types were analyzed separately and we
corrected for batch effects using ComBat of the R package sva. For the analysis of
differentially expressed (DE) genes, we applied a stringency level where the
adjusted p-value was less than 0.05 and the log2FC was less than −1 or greater than
1. For the heatmap we scaled the log2 expression values per gene by calculating the
mean expression per gene and then substracting that mean value of each expression
value.
RORγt compound. The RORγt agonist/inhibitor, BIX119, was discovered through
screening a small-molecule compound library. BIX119 strongly bound to the
human RORγ ligand-binding domain (LBD) and was active in a RORγ LBD
reporter assay (Kd for RORγ LBD – 65 nM; IC50 for RORγ LBD reporter assay
260 nM). The compound showed high selectivity towards RORγt as demonstrated
by a lack of signiﬁcant activity against RORα (IC50 > 10 μM) and RORβ (IC50 >
than 6 μM). In addition, BIX119 was inactive against a panel of 25 nuclear
receptors up to 10 μM. BIX119 potently inhibited IL-17A secretion from human
PBMCs activated with anti-CD3Abs and IL-23, as well as CD4+ Th17 cells sti-
mulated with anti-CD3/CD28/CD2 beads and a Th17 cytokine cocktail including
IL-1β, IL-23, IL-6, and TGFβ (IC50 10 nM and 17 nM, respectively). Levels of IL-17
and IL-22 in supernatants of compound experiments were determined by means of
ELISA using respecitively the human IL-17A Tissue Culture Kit (Meso Scale
Discovery) and the Human IL-22 Quantikine Kit (R&D Systems).
FlowSOM. Multiparameter ﬂow cytometry data derived from patient and control
samples, were subjected to FlowSOM21, which uses a self-organizing map (SOM) to
cluster and visualize the selected cell subsets (iNKT, TCRγδ, and Tconv) in dif-
ferent nodes based on the expression of distinct markers included in the ﬂow Ab
panel. For each subset, an aggregated ﬁle was created containing the cells from the
different samples, compensated and transformed as speciﬁed by the FlowJo
workspace and for the resulting aggregated ﬁles, a FlowSOM tree was trained. A
grid of 7 by 7 nodes, resulting in 49 clusters was used, which are visualized using
the Minimal Spanning Tree visualization. Scaling was set to FALSE and the
number of metaclusters to 10, all other parameters were kept as default. The
legends in the ﬁgures indicate which markers were used for clustering. The indi-
vidual ﬁles were mapped onto the trees to compute the percentage of cells assigned
to each cluster. The mean percentage per sample group was determined, and the
log10 fold change was computed to visualize the differences between the groups.
The log10 fold change was manually set to −2 (or a decrease by a 100 times less) if
no cells where present in the patient group (corresponding with a theoretical fold
change of -inﬁnity). A similar strategy was applied for the compound data, with
log10 fold change calculated for the condition with compound vs. no compound
(only vehicle). Additional information related to the interpretation of the Flow-
SOM tree ﬁgures is included in the ﬁgure legends.
Statistics. Data were analyzed using Prism software v5.0 (GraphPad) and SPSS
version 23 software. The Shapiro-Wilk test was used to test normality of the data.
Statistic tests (and annotations) are mentioned in the ﬁgures and ﬁgure legends. An
overview of statistics for Fig. 1f is provided in the Supplementary Table 3. In
general, the two-sided non-parametric Mann–Whitney U test was performed for
comparison of non-normality numeric data, whereas two-sided student’s (paired) t
test were used for normally distributed data. One-way analysis of variance
(ANOVA) were used for multi-group analyses of normally distributed data. Data is
presented as mean ± SEM unless stated otherwise. All the statistical assessments
were made at the 95% conﬁdence interval; p < 0.05 was considered to be statistically
signiﬁcant.
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
RNA-seq data from this study is deposited in GEO with accession code
GSE122624. Other data that support the ﬁndings of this study are available from
the corresponding authors upon reasonable request.
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